血管紧张素转换酶2与心血管疾病研究进展

摘要/Abstract

摘要： 血管紧张素转换酶2(ACE2)是SARS病毒(SARS-CoV)、新型冠状病毒(SARS-CoV-2)感染机体的主要受体,也是肾素-血管紧张素-醛固酮系统的主要成员之一。ACE2对多种心血管疾病具有保护作用,SARS-CoV-2可以降低机体ACE2的表达,这可能是新型冠状病毒肺炎(COVID-19)后期产生心血管并发症的原因之一。本文总结了ACE2在多种心血管疾病发病过程中的作用及其机制,希望为新型冠状病毒肺炎(COVID-19)的治疗提供新的思路。

关键词: 血管紧张素转换酶2, 心血管疾病, 肾素-血管紧张素-醛固酮系统

Abstract: Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV and SARS-CoV-2(severe acute respiratory syndrom coronavirus 2) viruses, and it is also one of the main family members of renin-angiotensin-aldosterone system. ACE2 has a protective effect on cardiovascular diseases and inhibits the development of cardiovascular diseases. SARS-CoV-2 reduces the expression of ACE2 of host, which may be one of the reasons for cardiovascular complications in the later stage of coronavirus disease 2019(COVID-19). Thus, the role and mechanism of ACE2 in the development of cardiovascular diseases were summarized in this article in order to provide potential stratigy development for the treatment of COVID-19.

Key words: angiotensin-converting enzyme 2, cardiovascular diseases, renin-angiotensin-aldosterone system

中图分类号:

焦晓璐, 秦彦文. 血管紧张素转换酶2与心血管疾病研究进展[J]. 基础医学与临床, 2020, 40(5): 701-706.

JIAO Xiao-lu, QIN Yan-wen. Progress of angiotensin converting enzyme 2 in cardiovascular diseases[J]. Basic & Clinical Medicine, 2020, 40(5): 701-706.

参考文献

[1]Alenina N, Bader M. ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models[J]. Neurochem Res, 2018, 44: 1323-1329.
[2]Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 10.1038/s41586-020-2012-7.
[3]Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism[J]. Biochem J, 2004, 383: 45-51.
[4]Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase[J]. J Biol Chem, 2002, 277: 14838-14843.
[5]Holmes L Jr, Lim A, Comeaux CR, et al. DNA methylation of candidate genes (ACE Ⅱ, IFN-gamma, AGTR 1, CKG, ADD1, SCNN1B and TLR2) in essential hypertension: a systematic review and quantitative evidence synthesis[J]. Int J Environ Res Pub Health, 2019, 16.doi:10.3390/ijerph16234829.
[6]Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China[J]. Lipids Health Dis, 2018, 17: 241.doi:10.1186/s12944-018-0890-6.
[7]Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism[J]. Life Sci, 2019, 225: 39-45.
[8]Xu J, Sriramula S, Xia HJ, et al. Clinical relevance and role of neuronal AT receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension[J]. Circ Res, 2017, 121: 43-55.
[9]Povlsen AL, Grimm D, Wehland M, et al. The vasoactive Mas receptor in essential hypertension[J]. J Clin Med, 2020, 9: 267.doi:10.3390/jcm9010267.
[10]Srivastava P, Badhwar S, Chandran DS, et al. Imbalance between Angiotensin Ⅱ-Angiotensin (1-7) system is associated with vascular endothelial dysfunction and inflammation in type 2 diabetes with newly diagnosed hypertension[J]. Diabetes Metab Syndr, 2019, 13: 2061-2068.
[11]Liao W, Fan H, Davidge ST, et al. Egg white-derived antihypertensive peptide IRW (Ile-Arg-Trp) reduces blood pressure in spontaneously hypertensive rats via the ACE2/Ang (1-7)/Mas receptor axis[J]. Mol Nutr Food Res, 2019, 67:7147-7156.
[12]Zhang L, Wang J, Liang JL et al. Propofol prevents human umbilical vein endothelial cell injury from AngⅡ-induced apoptosis by activating the ACE2-(1-7)-Mas axis and eNOS phosphorylation[J]. PLoS One, 2018, 13.doi:10.1371/journal.pone.0199373.
[13]Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin Ⅱ-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice[J]. Cell Metabolism, 2018, 27: 1323-1337.
[14]Zhao Y, Ma R, Yu X, et al. AHU377+valsartan (LCZ696) modulates renin-angiotensin system (RAS) in the cardiac of female spontaneously hypertensive rats compared with valsartan[J]. J Cardiovasc Pharmacol Ther, 2019, 24: 450-459.
[15]Zhao S, Ghosh A, Lo CS, et al. Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice[J]. Endocrinology, 2018, 159: 836-852.
[16]Wang K, Xu Y, Yang WK, et al. Insufficient hypotha-lamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats[J]. Oncotarget, 2017, 8: 20244-20251.
[17]Sriramula S, Xia H, Xu P, et al. Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation[J]. Hypertension, 2015, 65: 577-586.
[18]Mukerjee S, Gao H, Xu J, et al. ACE2 and ADAM17 interaction regulates the activity of presympathetic neurons[J]. Hypertension, 2019,74: 1181-1191.
[19]Shoemaker R, Tannock LR, Su W, et al. Adipocyte deficiency of ACE2 increases systolic blood pressures of obese female C57BL/6 mice[J]. Biol Sex Differ, 2019, 10:45-57.
[20]Minato T, Nirasawa S, Sato T, et al. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction[J]. Nat Commun, 2020, 11:1058-1070.
[21]Li Y, Hu J, Qian H, et al. Novel findings: Expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in thoracic aortic dissection and aneurysm[J]. J Renin-Angiotensin-Aldosterone Sys: JRAAS, 2015, 16: 1130-1134.
[22]Nie W, Wang Y, Yao K, et al. Serum angiotensin-converting enzyme 2 is an independent risk factor for in-hospital mortality following open surgical repair of ruptured abdominal aortic aneurysm[J]. Exp Ther Med, 2016, 12: 1412-1418.
[23]Moran CS, Biros E, Krishna SM, et al. Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2[J]. Arterioscler Thromb Vasc Biol, 2017, 37: 2195-2203.
[24]Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin Ⅱ-induced abdominal aortic aneurysms[J]. Arterioscler Thromb Vasc Biol, 2014, 34: 2617-2623.
[25]Hao Q, Dong X, Chen X, et al. Angiotensin-converting enzyme 2 inhibits angiotensin Ⅱ-induced abdominal aortic aneurysms in mice[J]. Hum Gene Ther, 2018.doi:10.1089/hum.2016.144.
[26]Zhou, X, Zhang P, Liang T, et al. Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease[J]. Heart Vessels, 2019, 35: 153-161.
[27]Anguiano L, Riera M, Pascual J, et al. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease[J]. Atherosclerosis, 2016, 253: 135-143.
[28]Zhang YH, Zhang YH, Dong XF, et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response[J]. Inflam Res, 2015, 64: 253-260.
[29]Stegbauer J, Thatcher SE, Yang G, et al. Mas receptor deficiency augments angiotensin Ⅱ-induced atherosclero-sis and aortic aneurysm ruptures in hypercholesterolemic male mice[J]. J Vasc Surg, 2019, 70: 1658-1668.e1651.
[30]Lin Y, Zeng H, Gao L, et al. Hydrogen sulfide attenuates atherosclerosis in a partially ligated carotid artery mouse model via regulating angiotensin converting enzyme 2 expression[J]. Front Physiol, 2017, 8:782.doi:10.3389/fphys.2017.00782.
[31]Pernomian L, do Prado AF, Gomes MS, et al. MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality[J]. Eur J Pharmacol, 2015, 764: 173-188.
[32]Sahara M, Ikutomi M, Morita T, et al. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation[J]. Cardiovasc Res, 2014, 101: 236-246.
[33]Chen Y, Wang X, Yang C, et al. Decreased circulating catestatin levels are associated with coronary artery disease: The emerging anti-inflammatory role[J]. Atherosclerosis, 2019, 281: 78-88.
[34]Zhang YH, Hao QQ, Wang XY, et al. ACE2 activity was increased in atherosclerotic plaque by losartan: Possible relation to anti-atherosclerosis[J]. J Renin Angiotensin Aldosterone Sys, 2014, 16: 292-300.
[35]Li S, Wang Z, Yang X, et al. Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients[J]. Peptides, 2017, 90: 63-68.
[36]Ramchand J, Patel SK, Kearney LG, et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associa-ted with severe myocardial fibrosis[J]. JACC Cardiovasc Imaging, 2019, 10.1016/j.jcmg.2019.09.005.
[37]Úri K, Fagyas M, Kertész A, et al. Circulating ACE2 activity correlates with cardiovascular disease development[J]. J Renin Angiotensin Aldosterone Sys, 2016, 17.doi:10.1177/1470320316668435.
[38]Katsi V, Maragkoudakis S, Marketou M, et al. The role of angiotensin-(1-7)/Mas axis and angiotensin type 2 receptors in the central nervous system in cardiovascular disease and therapeutics: a riddle to be solved[J]. Curr Vasc Pharmacol, 2019, 17: 319-325.
[39]Fan J, Zou L, Cui K, et al. Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Fan, ACE2 improves atrial substrate remodeling[J]. Basic Res Cardiol, 2015, 110: 45.doi:10.1007/s00395-015-0499-0.
[40]Sato T, Kadowaki A, Suzuki T, et al. Loss of apelin augments angiotensin Ⅱ-induced cardiac dysfunction and pathological remodeling[J]. Int J Mol Sci, 2019, 20.doi:10.3390/ijmsz0020239.
[41]de Oliveira Sa G, Dos Santos Neves V, de Oliveira Fraga SR, et al. High-intensity interval training has beneficial effects on cardiac remodeling through local renin-angiotensin system modulation in mice fed high-fat or high-fructose diets[J]. Life Sci, 2017, 189: 8-17.
[42]Sukumaran V, Tsuchimochi H, Tatsumi E, et al. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade[J]. Biochem Pharmacol, 2017, 144: 90-99.
[43]Joviano-Santos JV, Santos-Miranda A, Joca HC, et al. Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects[J]. Clin Exp Pharmacol Physiol, 2020, 47: 213-219.
[44]Badae NM, Naggar AS, Sayed SM. Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats?[J]. Can J Physiol Pharmacol, 2019, 97: 638-646.
[45]Castardeli C, Sartório CL, Pimentel EB, et al. The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats[J]. Biomed Pharmacother Biomed Pharmacother, 2018, 107: 212-218.
[46]Patel VB, Zhong JC, Grant MB, et al. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure[J]. Circ Res, 2016, 118: 1313-1326.
[47]Zhai CG, Xu YY, Tie YY, et al. DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensin-perfused animal model by regulating the ADAM17/ACE2 and GSK-3β/β-catenin pathways[J]. J Mol Cell Cardiol, 2018, 114: 243-252.
[48]Zhang ZZ, Cheng YW, Jin HY, et al. The sirtuin 6 prevents angiotensin Ⅱ-mediated myocardial fibrosis and injury by targeting AMPK-ACE2 signaling[J]. Oncotarget, 2017, 8: 72302-72314.
[49]Lai L, Chen J, Wang N, et al. miR-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy[J]. Life Sci, 2017, 169: 69-75.
[50]Qi YF, Zhang J, Wang L, et al. Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia[J]. J Mol Med (Berlin, Germany), 2016. 94: 37-49.
[51]Patel VB, Mori J, McLean BA, et al. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity[J]. Diabetes, 2016, 65: 85-95.
[52]Walters TE, Kalman JM, Patel SK, et al. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling[J]. Europace: Eur Pacing Arrhyth Cardiac Electrophysiol, 2017, 19: 1280-1287.
[53]Coutinho DC, Monnerat-Cahli G, Ferreira AJ, et al. Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats[J]. Europace: Eur Pacing Arrhyth Cardiac Electrophysiol, 2014, 16: 1689-1696.
[54]Hemnes AR, Rathinasabapathy A, Austin EA, et al. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension[J]. Eur Respir J, 2018, 51.doi:10.1183/13993003.02638-2017.